Skip to the main content

Case report

https://doi.org/10.20471/acc.2020.59.04.25

Oxaliplatin Induced Pulmonary Fibrosis: a Case Report

Mirjana Pavlović orcid id orcid.org/0000-0002-9633-064X ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Robert Šeparović orcid id orcid.org/0000-0002-4002-2699 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Tajana Silovski orcid id orcid.org/0000-0002-4699-5432 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Ana Tečić Vuger orcid id orcid.org/0000-0003-2203-161X ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia
Andreja Jurić orcid id orcid.org/0000-0002-7539-2278 ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Medical Oncology, Zagreb, Croatia


Full text: english pdf 371 Kb

page 761-764

downloads: 633

cite


Abstract

Oxaliplatin is part of the standard chemotherapy regimens for treating colorectal
carcinoma. Pulmonary fibrosis is a serious but rare side effect of oxaliplatin treatment, which resulted
in patient death in more than half of the reported cases. The precise pathophysiological mechanism of
this phenomenon has not been clarified yet. Analysis of the reported cases strongly suggests that
early diagnosis and immediate corticosteroid treatment are crucial for better prognosis. Here we report
a case of pulmonary fibrosis related to the FOLFOX regimen in a patient with early colorectal
carcinoma.

Keywords

Oxaliplatin; Colon cancer; Side effects; Pulmonary fibrosis; Interstitial lung disease

Hrčak ID:

255233

URI

https://hrcak.srce.hr/255233

Publication date:

1.12.2020.

Article data in other languages: croatian

Visits: 2.274 *